financetom
Business
financetom
/
Business
/
Nvidia Fiscal Q3 Adjusted Earnings, Revenue Rise; Fiscal Q4 Revenue Outlook Set; Dividend Maintained
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nvidia Fiscal Q3 Adjusted Earnings, Revenue Rise; Fiscal Q4 Revenue Outlook Set; Dividend Maintained
Nov 19, 2025 1:52 PM

04:26 PM EST, 11/19/2025 (MT Newswires) -- Nvidia ( NVDA ) reported fiscal Q3 adjusted earnings late Wednesday of $1.30 per diluted share, up from $0.81 a year earlier.

Analysts polled by FactSet expected $1.26.

Revenue for the three months ended Oct. 26 was $57.01 billion, up from $35.08 billion a year earlier.

Analysts surveyed by FactSet expected $54.91 billion.

The company expects fiscal Q4 revenue of $65 billion, plus or minus 2%. Analysts expect $62.17 billion.

The company maintained its quarterly dividend at $0.01 per share, payable Dec. 26 to stockholders of record Dec. 4.

Nvidia ( NVDA ) shares rose 2.5% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cemtrex to Acquire Invocon for $7.06 Million
Cemtrex to Acquire Invocon for $7.06 Million
Nov 20, 2025
01:59 PM EST, 11/20/2025 (MT Newswires) -- Cemtrex ( CETX ) said Thursday it has agreed to acquire Invocon, a Texas-based aerospace and defense engineering firm, for $7.06 million. The deal, which is subject to customary closing conditions, is expected to close on or around Jan. 1, 2026, the company said. After the acquisition closes, Cemtrex ( CETX ) plans...
Medexus Pharmaceuticals to Launch Normal Course Issuer Bid
Medexus Pharmaceuticals to Launch Normal Course Issuer Bid
Nov 20, 2025
01:58 PM EST, 11/20/2025 (MT Newswires) -- Medexus Pharmaceuticals ( MEDXF ) on Thursday said it received exchange approvals to launch a normal course issuer bid (NCIB).. The company may buy back for cancellation up to 2.98-million shares, about 10% of the public float. As of Nov. 12, the company had 32.4-million shares outstanding and a public float of 29.8-million...
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat
Nov 20, 2025
Vanda Pharmaceuticals Inc. ( VNDA ) on Monday released topline results from its randomized controlled clinical study (VP-VLY-686-2601) evaluating tradipitant to prevent nausea and vomiting induced by Novo Nordisk A/S ( NVO ) Wegovy. • Get the market research on VNDA stock here. The trial studied 116 healthy overweight or obese adults. The study saw 29.3% of tradipitant-treated participants (17/58)...
Provident Healthcare Partners Advises Meperia in its Acquisition by Diversis Capital
Provident Healthcare Partners Advises Meperia in its Acquisition by Diversis Capital
Nov 20, 2025
BOSTON, Nov. 20, 2025 /PRNewswire/ -- Provident Healthcare Partners (Provident), a leading healthcare investment banking firm, is pleased to announce it has advised Meperia, a supply chain and strategic sourcing platform serving Integrated Delivery Networks (IDNs). Provident also facilitated Diversis in the acquisition of Kermit, a bill-only, spend management, and analytics platform for physician preference items (PPI). This transaction marks...
Copyright 2023-2026 - www.financetom.com All Rights Reserved